After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Fears that Humira biosimilars will erode AbbVie's top line ... Please watch the video at Investors.com - How To Buy Stocks: Flat Base Chart Pattern On Friday, AbbVie beat first-quarter ...

As a medication vital for improving patient outcomes, Humira's high cost presents employers with the challenge of balancing financial considerations with the opportunities offered by biosimilars ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Since we rolled out Connect 360 Autoimmune in 2023, we’ve transitioned over 90% of our members to the biosimilar, Yusimry, and lowered Humira spend for clients by 90%.” In addition to the ...